These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 4722544)

  • 21. Phentolamine inhibition of human growth hormone secretion induced by L-DOPA.
    Cammani F; Massara F
    Horm Metab Res; 1972 Mar; 4(2):128. PubMed ID: 4554974
    [No Abstract]   [Full Text] [Related]  

  • 22. The Albright syndrome associated with acromegaly: report of a case and review of the literature.
    Lipson A; Hsu TH
    Johns Hopkins Med J; 1981 Jul; 149(1):10-4. PubMed ID: 7019531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in plasma growth hormone levels after surgical treatment of acromegaly.
    Jacobs HS; Greenwood FC; Nabarro JD
    Proc R Soc Med; 1970 Mar; 63(3):223-4. PubMed ID: 5445553
    [No Abstract]   [Full Text] [Related]  

  • 24. The response of serum growth hormone to central and peripheral dopaminergic stimuli in normal subjects and in acromegalic patients.
    Oma H; Kato K; Takahashi H; Ibayashi H
    Fukuoka Igaku Zasshi; 1982 Mar; 73(3):179-88. PubMed ID: 7106688
    [No Abstract]   [Full Text] [Related]  

  • 25. Use of the oral glucose tolerance test to define remission in acromegaly.
    Vierhapper H; Heinze G; Gessl A; Exner M; Bieglmayr C
    Metabolism; 2003 Feb; 52(2):181-5. PubMed ID: 12601629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. L-dopa therapy in parkinsonism: mechanism of action.
    Sandler M
    Psychiatr Neurol Neurochir; 1971; 74(4):331-3. PubMed ID: 5146239
    [No Abstract]   [Full Text] [Related]  

  • 27. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.
    Minniti G; Jaffrain-Rea ML; Osti M; Esposito V; Santoro A; Solda F; Gargiulo P; Tamburrano G; Enrici RM
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):210-6. PubMed ID: 15670198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of L-dopa on the EEG and EMG in Parkinson patients.
    Visser SL; Postma JU
    Psychiatr Neurol Neurochir; 1971; 74(4):315-21. PubMed ID: 5146237
    [No Abstract]   [Full Text] [Related]  

  • 29. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [L-dopa and somatotropin secretion in humans].
    Giordano G; Marugo M; Minuto F; Barreca T; Foppiani E
    Folia Endocrinol; 1973 Dec; 26(6):523-37. PubMed ID: 4801262
    [No Abstract]   [Full Text] [Related]  

  • 31. Homocysteine levels in acromegaly patients.
    Hekimsoy Z; Ozmen B; Ulusoy S
    Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Peripheral thyroid function and TRH-TSH test in patients with acromegaly].
    Heberling HJ; Heilmann W; Ulrich FE; Schneyer U
    Z Gesamte Inn Med; 1981 Apr; 36(8):306-8. PubMed ID: 6792802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
    Minuto F; Resmini E; Boschetti M; Arvigo M; Sormani MP; Giusti M; Ferone D; Barreca A
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of somatostatin in parkinsonism, growth hormone, and dopa metabolism.
    Papavasiliou PS; Cotzias GC; Rubin JI; Rosal VL; Wang YY
    Trans Am Neurol Assoc; 1977; 102():90-3. PubMed ID: 616124
    [No Abstract]   [Full Text] [Related]  

  • 35. Growth hormone abnormalities in Huntington's chorea: effect of L-dopa administration.
    Podolsky S; Leopold NA
    J Clin Endocrinol Metab; 1974 Jul; 39(1):36-9. PubMed ID: 4276011
    [No Abstract]   [Full Text] [Related]  

  • 36. [Acromegaly].
    Warnet A
    Soins; 1988 Jul; (514):26-30. PubMed ID: 2903558
    [No Abstract]   [Full Text] [Related]  

  • 37. Corticosteroid and growth hormone secretion in patients treated with L-dopa.
    von Werder K; van Loon GR; Yatsu F; Forsham PH
    Klin Wochenschr; 1970 Dec; 48(24):1454-6. PubMed ID: 4324569
    [No Abstract]   [Full Text] [Related]  

  • 38. [CB-154 (2-brom-alpha-ergocryptine) loading test].
    Shizume K; Kozuka N
    Nihon Rinsho; 1979 Jun; Suppl():2471-2. PubMed ID: 491190
    [No Abstract]   [Full Text] [Related]  

  • 39. L-dopa and error correction time in Parkinson's disease.
    Angel RW; Alston W; Garland H
    Neurology; 1971 Dec; 21(12):1255-60. PubMed ID: 5167317
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of L-Phenylalanine absorption by L-DOPA in patients with parkinsonism.
    Granerus AK; Jagenburg R; Rödjer S; Svanborg A
    Proc Soc Exp Biol Med; 1971 Jul; 137(3):942-4. PubMed ID: 5560686
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.